Veterinary Record 145:191-194 doi:10.1136/vr.145.7.191
  • Papers & Articles

Clinical anti-inflammatory efficacy of arofylline, a new selective phosphodiesterase-4 inhibitor, in dogs with atopic dermatitis

  1. A. Puigdemont, Pharm,PhD1
  1. 1 Departament de Farmacologia i Terapèutica
  2. 2 Department de Patologia i Producció Animals, Facultat de Veterinaria, Universitat Autònoma de Barcelona, 08193 Bellaterra, Barcelona, Spain
  3. 3 Almirall Prodesfarma, Barcelona, Spain


Forty atopic dogs were studied for 28 days after the oral administration of four randomised treatments: (A) arofylline (1 mg/kg) twice daily for four weeks; (B) prednisone (0.5 mg/kg) twice daily for the first week, once a day during the second week and every 48 hours for the remaining two weeks; (C) prednisone following the same protocol but at a dose of 0-25 mg/kg; or (D) arofylline (1 mg/kg) twice daily for four weeks plus prednisone (0.25 mg/kg) following the same protocol as in (B) and (C). The degree of pruritus and skin lesions and the side effects were evaluated and graded from 0 to 3 before and weekly during the treatments. In all cases there was a progressive clinical improvement in the clinical signs, with no statistical differences among the four treatments. However, many of the dogs treated with arofylline vomited and had adverse gastrointestinal signs.

    Sign up for job alerts

    Vet Record Careers features a comprehensive database of vet jobs.
    Browse for your next job, or set personalised job alerts so you hear about vacancies as soon as they go online.
    Find out more at Vet Record Careers

    Free Sample Issue

    This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of the Veterinary Record.
    View free sample issue >>

    Navigate This Article